Analyst Price Targets — PODD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 19, 2026 2:04 pm | — | Truist Financial | $360.00 | $246.04 | TheFly | Insulet price target lowered to $360 from $390 at Truist |
| February 19, 2026 1:19 pm | — | Evercore ISI | $340.00 | $251.21 | TheFly | Insulet price target lowered to $340 from $370 at Evercore ISI |
| February 19, 2026 12:58 pm | David Roman | Goldman Sachs | $326.00 | $251.38 | TheFly | Insulet price target lowered to $326 from $363 at Goldman Sachs |
| February 19, 2026 12:46 pm | — | Oppenheimer | $300.00 | $254.59 | TheFly | Insulet price target lowered to $300 from $365 at Oppenheimer |
| February 19, 2026 12:38 pm | — | Bernstein | $330.00 | $258.07 | TheFly | Insulet price target lowered to $330 from $380 at Bernstein |
| February 19, 2026 11:35 am | — | Barclays | $286.00 | $258.07 | TheFly | Insulet price target raised to $286 from $274 at Barclays |
| February 18, 2026 9:43 pm | William Plovanic | Canaccord Genuity | $435.00 | $258.07 | StreetInsider | Insulet Corporation (PODD) PT Lowered to $435 at Canaccord Genuity |
| February 4, 2026 1:09 pm | — | Stifel Nicolaus | $350.00 | $249.07 | TheFly | Insulet price target lowered to $350 from $370 at Stifel |
| January 12, 2026 1:36 pm | — | Barclays | $274.00 | $286.92 | TheFly | Insulet downgraded to Underweight from Equal Weight at Barclays |
| January 9, 2026 11:50 am | Lee Hambright | Bernstein | $380.00 | $292.89 | TheFly | Insulet price target lowered to $380 from $410 at Bernstein |
Latest News for PODD
DNB Asset Management AS boosted its stake in Insulet Corporation (NASDAQ: PODD) by 5.2% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 48,013 shares of the medical instruments supplier's stock after purchasing an additional 2,379 shares during the
United Health Products (OTCMKTS:UEEC - Get Free Report) and Insulet (NASDAQ: PODD - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends. Risk and Volatility United Health Products has a
Aster Capital Management DIFC Ltd grew its holdings in shares of Insulet Corporation (NASDAQ: PODD) by 1,015.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,979 shares of the medical instruments supplier's stock after buying an additional
Andra AP fonden boosted its stake in shares of Insulet Corporation (NASDAQ: PODD) by 50.0% in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 86,400 shares of the medical instruments supplier's stock after acquiring an additional 28,800 shares during the period. Andra AP fonden owned
The market is overstating the impact of GLP-1s and fails to recognize that GLP-1s pose no direct threat to Insulet's customer base. International expansion into Europe (the largest addressable market for T1D) and the shift into MENA focus will drive top-line growth. The T2D market is underpenetrated, representing a wide potential runway, from which PODD is set to win the most based on structural moats.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.